P1101 + Low-dose aspirin

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera (PV)

Conditions

Polycythemia Vera (PV)

Trial Timeline

Dec 20, 2019 → Mar 8, 2021

NCT ID

NCT04182100

About P1101 + Low-dose aspirin

P1101 + Low-dose aspirin is a phase 2 stage product being developed by PharmaEssentia for Polycythemia Vera (PV). The current trial status is completed. This product is registered under clinical trial identifier NCT04182100. Target conditions include Polycythemia Vera (PV).

What happened to similar drugs?

2 of 17 similar drugs in Polycythemia Vera (PV) were approved

Approved (2) Terminated (1) Active (15)

🔄Sapablursen + PlaceboOno PharmaceuticalPhase 3

🔄Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3

🔄ruxolitinib tabletsNovartisPhase 3

🔄RuxolitinibNovartisPhase 3

✅HydroxyureaNovartisApproved

🔄Best Available Therapy + RuxolitinibNovartisPhase 3

🔄PEGASYS + Hydroxyurea + AspirinRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06002490	Phase 3	Completed	Oct 17, 2023	Jul 26, 2024	Polycythemia Vera (PV)
NCT04182100	Phase 2	Completed	Dec 20, 2019	Mar 8, 2021	Polycythemia Vera (PV)

Competing Products

20 competing products in Polycythemia Vera (PV)

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	47
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Bomedemstat	Merck	Phase 2	35
Ruxolitinib + Hydroxycarbamide + Interferon-Alpha	Novartis	Phase 3	47
ruxolitinib tablets	Novartis	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ruxolitinib	Novartis	Phase 3	40
Ruxolitinib + BAT	Novartis	Phase 2	39
Hydroxyurea	Novartis	Approved	35
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	40
Smac Mimetic LCL161	Novartis	Phase 2	35
PEGASYS + Aspirin	Roche	Phase 2	35
RG7388 + Pegasys	Roche	Phase 1	29
Idasanutlin	Roche	Phase 2	27
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Phase 2	39
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	PharmaEssentia	Phase 3	40
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Approved	50
P1101 (Ropeginterferon alfa-2b)	PharmaEssentia	Phase 3	47